OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Related Content:
News